Hypoparathyroidism

EQS-News: Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Retrieved on: 
Wednesday, April 10, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Sale, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Pharma, Hypoparathyroidism, Fine chemical

Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca

Key Points: 
  • Amolyt Pharma, an Andera Partners’ portfolio company, announces its sale to AstraZeneca
    The issuer is solely responsible for the content of this announcement.
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • The company led by Thierry Abribat and an exceptional management team has developed innovative therapies for rare endocrine diseases.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Amolyt Pharma Enters into Definitive Agreement to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
PTHR1, AstraZeneca, Acromegaly, Patient, Acquisition, Endocrine disease, Cooley LLP, Centerview Partners, Alexion, Hypoparathyroidism, Pharmaceutical industry

LYON, France and CAMBRIDGE, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced it has entered into a definitive agreement for AstraZeneca to acquire Amolyt Pharma at a purchase price of $800 million upfront and a potential milestone payment of $250 million. Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.

Key Points: 
  • Alexion, AstraZeneca Rare Disease is looking forward to welcoming talent from Amolyt Pharma.
  • We are grateful to the investigators, patients, and patient associations who have supported us to reach these goals,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • Under the terms of the agreement, AstraZeneca will acquire all of Amolyt Pharma’s outstanding shares for a total consideration of up to $1.05B, on a cash and debt free basis.
  • Centerview Partners LLC and Goldman Sachs Bank Europe SE acted as financial advisors to Amolyt, and Cooley LLP and Jones Day acted as legal counsels for Amolyt and its shareholders.

Sofinnova Partners Portfolio Company Amolyt Pharma to be Acquired by AstraZeneca

Retrieved on: 
Thursday, March 14, 2024
Professional Services, Health, Other Health, Finance, Clinical Trials, Pharmaceutical, Biotechnology, Partner, PTHR1, AstraZeneca, Disease, Acromegaly, Patient, Lead, Acquisition, Endocrine disease, Cooley LLP, Investment, Series, Centerview Partners, Alexion, Endocrinology, Hypoparathyroidism

We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.

Key Points: 
  • We are thankful to Sofinnova Partners and all the investors for their continued confidence in our team and for their support of our strategy,” said Thierry Abribat, Ph.D., Founder and Chief Executive Officer of Amolyt Pharma.
  • “Congratulations to the Amolyt team on its proposed acquisition by AstraZeneca.
  • Thierry, is a visionary leader and embodies the serial biotech entrepreneurs we partner with,” added Antoine Papiernik, Managing Partner & Chairman of Sofinnova Partners.
  • Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage.

Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
Friday, March 8, 2024
OXM, Woman, Injection, Research, Bone fracture, Clinical research associate, Type D, FDA, BMD, PTH, Food, Hypoparathyroidism, Obesity, Coeliac disease, Weight loss, Oxyntomodulin, Cmax, Elective surgery, Sport, Short bowel syndrome, OPKO Health, DSM-IV codes, Ecosystem, SABRE, Patient, D&O, Intellectual property, Fracture, Athlete, Sports medicine, Tablet, Osteoporosis, Insurance

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023.
  • Following our December 2023 financing, we expect to have sufficient cash to fund operations through the first half of 2025,” said Miranda Toledano, CEO of Entera.
  • Financial Results for the year Ended December 31, 2023
    As of December 31, 2023, Entera had cash and cash equivalents of $11.0 million.
  • Operating expenses for year ended December 31, 2023 were $8.9 million, as compared to $13.0 million for the year ended December 31, 2022.

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, McKinsey & Company, Shalini, Bristol Myers Squibb, Lactococcus lactis, Harvard University, Organon, Agenus, Patient, GPCR, Drug discovery, MBA, Endocrinology, Neurocrine Biosciences, Therapy, Assistant, Drug development, Hypoparathyroidism, Acquisition, Goldman Sachs, G protein-coupled receptor, Metabolism, University, Mirati Therapeutics, PTH1R, Precigen, Pharmacy, Internal medicine, Pharmaceutical industry

Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.

Key Points: 
  • Dr. Coulie and Ms. Sharp bring deep drug development and company-building experience to Septerna’s board.
  • Shalini brings a wealth of strategic, financial, and operational experience, having led or advised several successful private and public biotech companies.
  • Bernard Coulie brings more than two decades of senior leadership experience and drug development expertise to the Septerna board.
  • Shalini Sharp has been in the life sciences industry for over 25 years, having spent 14 years as a Chief Financial Officer.

MBX Biosciences Appoints Steven Ryder, M.D., to Board of Directors

Retrieved on: 
Monday, February 5, 2024
Pfizer, Growth, PEP, Therapy, Patient, BIO, Alexion Pharmaceuticals, Head, Food, Reata Pharmaceuticals, Society, Health, Regulation, Science, Hypoparathyroidism, Biotechnology Innovation Organization, Pharmacy, Pharmaceutical industry

CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.

Key Points: 
  • CARMEL, Ind., Feb. 05, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. , a clinical-stage biopharmaceutical company developing Precision Endocrine Peptide™ (PEP™) therapeutics to treat an array of endocrine disorders, today announced the appointment of Steven Ryder, M.D., Chief Medical Officer of Rallybio, to its Board of Directors.
  • Dr. Ryder is an accomplished biopharmaceutical executive with over 35 years of global drug development experience and industry leadership.
  • “I am delighted to welcome Steve to our Board of Directors, and we look forward to his leadership as we progress our pipeline of novel therapies for people with rare endocrine disorders,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences.
  • “I am honored to join the MBX Board during this exciting period of growth for the Company,” said Dr. Ryder.

Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

Retrieved on: 
Wednesday, January 31, 2024
Vision 2030, PTH, Patient, Physician, Parathyroid hormone, Hypoparathyroidism, Pharmaceutical industry

COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that YORVIPATH® (palopegteriparatide, developed as TransCon PTH), a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism, is now available in Germany and Austria.
  • YORVIPATH is the second product developed with Ascendis Pharma’s TransCon technology platform to be launched commercially.
  • “We are pleased to initiate the launch of YORVIPATH to address the needs expressed within the hypoparathyroidism community for a new PTH-based treatment option,” said Jan Mikkelsen, Ascendis Pharma’s President and Chief Executive Officer.
  • With an increasingly broad commercial infrastructure in place, we are well positioned to accomplish this by expanding the availability of YORVIPATH and our other approved products to meet the needs of physicians and patients around the world.”

Vector Pharma FZCO Announce Exclusive Distribution Agreement with Ascendis Pharma A/S for Skytrofa (lonapegsomatropin) and Yorvipath (palopegteriparatide) in Gulf Cooperation Council Countries 

Retrieved on: 
Monday, January 8, 2024
Marketing, Hypoparathyroidism, European Commission, GHD, Vector, Health professional, European, Patient, Gulf Cooperation Council, GCC, Therapy, Pharmaceutical industry

DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa™ and Yorvipath™ in the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain.

Key Points: 
  • DUBAI, United Arab Emirates, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Vector Pharma FZCO (Vector) today announced that it has entered into an exclusive distribution agreement with Danish company Ascendis Pharma A/S (Nasdaq: ASND) to commercialize both Skytrofa™ and Yorvipath™ in the Gulf Cooperation Council (GCC) countries of Saudi Arabia, United Arab Emirates, Kuwait, Oman, Qatar and Bahrain.
  • Under the terms of this exclusive distribution agreement, Vector will employ its sales and marketing expertise to distribute both Skytrofa and Yorvipath to patients in the GCC countries for the treatment of pediatric growth hormone deficiency (GHD) in the case of Skytrofa, and adult hypoparathyroidism in the case of Yorvipath.
  • “I am excited to announce this regional agreement with Ascendis Pharma,” commented Vector Pharma FZCO Managing Partner, Patrick Jordan.
  • “Their deep experience in the region will support our shared goal of bringing to market new treatment options designed to address the needs of patients living with these rare diseases.”

Ascendis Pharma Introduces Vision 2030

Retrieved on: 
Sunday, January 7, 2024
Growth hormone, Vision 2030, Patient, Endocrine gland, Hypoparathyroidism, Conference, Achondroplasia, Turner syndrome, FDA, GHD, PDUFA, Globalization, Investigational New Drug, New Drug Application, Transgender hormone therapy, J. P. Morgan, Ophthalmology, CNP, HNSCC, Growth, CTA, Pharmaceutical industry

COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030. Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference.

Key Points: 
  • COPENHAGEN, Denmark, Jan. 07, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today introduced selected 2024 corporate milestones and Vision 2030, its strategic roadmap through 2030.
  • Ascendis President and CEO Jan Mikkelsen will present the update tomorrow, January 8, at the 42nd Annual J.P. Morgan Healthcare Conference.
  • Topline results from Phase 2 trial in Turner syndrome expected in the fourth quarter of 2024.
  • The Company’s slides from the J.P. Morgan presentation will be available on the same Investor Relations website at https://investors.ascendispharma.com .

Specialised Therapeutics signs exclusive agreement with Ascendis Pharma A/S for distribution and commercialisation of three endocrinology therapies in Australia and select South-East Asia countries

Retrieved on: 
Sunday, January 7, 2024
Growth hormone, Hypoparathyroidism, Quality of life, Partnership, Achondroplasia, Vitamin D, ACH, European, Disease, Osteochondrodysplasia, Therapy, PTH, Endocrinology, CNP, Patient, Phase II, Pharmaceutical industry

Under the terms of the agreement, ST will commercialise Ascendis Pharma's weekly injectable paediatric human growth hormone treatment SKYTROFATM (lonapegsomatropin), hypoparathyroidism treatment YORVIPATHTM (palopegteriparatide) and investigational achondroplasia therapy TransCon™ CNP (navepegritide).

Key Points: 
  • Under the terms of the agreement, ST will commercialise Ascendis Pharma's weekly injectable paediatric human growth hormone treatment SKYTROFATM (lonapegsomatropin), hypoparathyroidism treatment YORVIPATHTM (palopegteriparatide) and investigational achondroplasia therapy TransCon™ CNP (navepegritide).
  • The agreement spans ST's key regions of Australia, New Zealand, Singapore, Malaysia, Brunei, Thailand, and Vietnam.
  • Announcing the partnership, ST Chief Executive Officer Carlo Montagner said this agreement was an important company milestone, signalling ST's expansion into both endocrinology and paediatric medicine.
  • "We are delighted to partner with Specialised Therapeutics to broaden the reach of our endocrinology rare disease portfolio, contributing to our shared goal of making a meaningful difference for patients facing unmet medical needs," she said.